Manage Complex Care Tracking With Oncology MIPS Reporting

Your team delivers the care. Oncology MIPS reporting often breaks in places few practices look. A patient gets infusions in a hospital suite, oral chemotherapy at home, and pain checks over telehealth. Each handoff can drop that patient from a quality denominator. A weak final score costs up to -9% on Medicare Part B payments two years later.

This guide explains what CMS expects from cancer care teams under the current Quality Payment Program. It covers the Advancing Cancer Care MVP, the measures that trip up infusion clinics, cost scoring, and the coding fixes that keep treated patients counted.

What Does MIPS Require From Oncology Practices?

Oncology clinicians who exceed the Medicare Part B low-volume threshold must report MIPS and reach 75 points to avoid a penalty. CMS holds the 75-point performance threshold steady through three performance years, per the CMS final rule fact sheet.

Eligibility follows 42 CFR 414.1305. A clinician or group is exempt when any one of these is true:

$90,000 or less in allowed charges for covered professional services.
200 or fewer Part B patients.
200 or fewer covered professional services.

Four categories build the final score:

Quality (30%): six measures, one outcome or high priority, full year, 75% data completeness.
Cost (30%): calculated by CMS from claims.
Promoting Interoperability (25%): 180 days on certified EHR technology (CEHRT).
Improvement Activities (15%): 90 days per activity.

A score of 18.75 or below draws the full -9% adjustment. Scores above 75 earn a positive adjustment scaled for budget neutrality.

Which Reporting Path Fits an Oncology Group: Traditional MIPS, MVP, or APP?

Most independent oncology groups choose between traditional MIPS and the Advancing Cancer Care MVP (ID M0001). Practices in the Enhancing Oncology Model (EOM) can report through the APM Performance Pathway (APP).

The MVP trims the workload. You report four quality measures instead of six and one improvement activity instead of two. CMS calculates population health measures #479 and #484 from claims and keeps the higher score. Our MVP transition guide walks through the switch.

Structure rules decide who can register:

27 MVPs are open this performance year.
Multispecialty groups must report an MVP as subgroups, as individuals, or as an APM Entity.
Small practices (15 or fewer clinicians) may register as one group after attesting to their specialty composition.

A cancer center billing under a hospital’s multispecialty TIN will likely need an oncology subgroup.

CMS extended EOM into a seven-year model test. Both risk arrangements count as MIPS APMs, and Risk Arrangement 2 meets Advanced APM criteria, per the CMS EOM FAQ.

Which Oncology Quality Measures Should You Report?

Choose measures with large, clean denominators and real room to score. Measures 143 and 144 are simple to perform. Both carry a flat topped-out benchmark this performance year. Only a 100% rate earns 10 points, and a 95% rate earns 6 to 6.9.

Measure	What CMS tracks	Collection type	Key codes or trap
#143 Pain Intensity Quantified	Pain scored at each visit during chemo or radiation	MIPS CQM, eCQM	1125F pain present, 1126F no pain, 1125F-8P not met
#144 Plan of Care for Pain	Plan documented when pain is present	MIPS CQM	0521F; denominator comes only from #143 visits coded 1125F
#047 Advance Care Plan	Advance care plan documented	Part B claims, MIPS CQM	Claims route open to small practices
#453 Systemic therapy in last 14 days of life	End-of-life treatment intensity	MIPS CQM	Inverse: a lower rate scores better
#457 Hospice stay under 3 days	Late hospice admission	MIPS CQM	Inverse; tied to goals-of-care timing
#450, #451, #507	HER2 therapy, RAS testing, germline testing	MIPS CQM	Pathology and genomic results must sit in structured fields
#462 Bone Density With ADT	Prostate cancer patients on androgen deprivation therapy	eCQM, MIPS CQM	DXA order and result must reach your EHR

Report extra measures when the data supports them. CMS counts the highest-scoring measures toward your total.

Why Do Treated Cancer Patients Drop Out of Measure Denominators?

Patients drop out when your registry feed misses one link in the denominator logic. The measure 143 specification requires a cancer code (C00-C96 or D37-D49), a qualifying visit, and chemotherapy on two different days: One within 30 days before the visit and one within 30 days after.

Where the chain breaks:

Hospital-based infusion: The facility bills CPT 96413 on its institutional claim. The oncologist’s claim shows only the E/M visit. Pull administration dates from the EHR medication record.
Same-day doses: Two administrations on one date do not qualify.
Oral regimens. Codes M1433 and M1434 keep oral therapy patients in the chemotherapy group.
History codes: Z85.- codes sit outside the denominator list. ICD-10-CM guidelines reserve them for patients with no further treatment directed at the site.
Radiation visits: Code 77427 pulls patients in by billing date. The pain check must happen within a 7-day lookback. Telehealth radiation visits are excluded.
Telehealth chemotherapy visits qualify with codes 98000-98007.

How Does CMS Score the Cost Category for Oncologists?

CMS scores cost from administrative claims, and you submit nothing. Under M0001, oncology clinicians face the Prostate Cancer episode-based measure and Total Per Capita Cost (TPCC) once case minimums are met.

The prostate cancer measure is a chronic-condition episode with a case minimum of 20. It draws on Medicare Part D data, which pulls oral drug spending into the score, per the CMS cost measure summary.
CMS revised TPCC attribution. Visits billed by nurse practitioners or physician assistants no longer trigger TPCC when every other clinician in the group is specialty-excluded.
Any new cost measure now runs for two years as feedback only before it affects a final score.

Hematology-oncology groups with large advanced practice provider teams gain the most from the TPCC fix. Check your feedback report for TPCC attribution built on NP or PA visits alone.

How Can Billing Teams Protect Oncology Quality Data on Every Claim?

Treat every infusion-cycle claim as quality data. Reconcile remittance advice, corrected claims, and registry extracts monthly.

A dependable audit routine:

Match each paid E/M date on the 835 remittance advice to chemotherapy dates from the practice or the hospital.
Flag visits coded Z85.3 or another history code where the note shows active therapy. Query the clinician before release.
Refresh the registry extract after any replacement claim. Stale extracts keep the original diagnosis.
Confirm 1125F or 1126F on every chemotherapy-cycle visit. Rising 8P counts point to template gaps.
Track data completeness monthly against the 75% floor.

A diagnosis-to-procedure denial on an infusion line is a MIPS warning sign. The coding gap behind it often removes the patient from measure 143. Our guide on how clean claims lift quality scores covers the front-end fixes.

When Should Oncology Teams Lock In Each MIPS Deadline?

Quality covers the full calendar year. Promoting Interoperability and Improvement Activities need continuous windows that close earlier.

Promoting Interoperability: 180 consecutive days, with a latest start in early July. The Security Risk Analysis measure adds a security risk management attestation. The SAFER Guide measure uses the updated High Priority Practices guide. A “No” on either zeroes the category.
Improvement Activities: 90 consecutive days, with a latest start in early October. Traditional MIPS requires two activities, or one for small practices. Cancer-focused options include IA_BE_24 Financial Navigation Program, IA_CC_17 Patient Navigator Program, and IA_PM_21 Advance Care Planning.
Retired activities: CMS removed IA_CC_1 (closing referral loops) and IA_CC_2 (timely test result communication). Teams using them need a replacement.
MVP registration: April 1 through December 1.

See what a full-year submission includes on our MIPS reporting services 2026 page.

Conclusion

This guide matched current MIPS rules to the daily work of cancer care teams. It covered eligibility, category weights, and the 75-point threshold. It compared traditional MIPS, the Advancing Cancer Care MVP, and the APP for EOM practices. It showed why treated patients fall out of quality denominators and how cost scoring changed. It closed with a billing audit routine and the deadlines that matter most.

Keep Every Treated Patient in Your MIPS Data

Our team reviews measure selection, registry extracts, and claims data before you submit. See where your oncology score stands.

Book Your Oncology MIPS Review

Frequently Asked Questions

Can a clinician report more than one MVP in a performance year?

No. Each MVP participant reports one MVP per performance period. The MVP chosen at registration cannot change after the registration window closes.

Does a clinician in an Advanced APM still face MIPS?

Yes, unless the clinician reaches Qualifying APM Participant (QP) status or another exception applies. CMS now checks QP status for each individual clinician, not only the APM Entity.

What if a registry cannot support a newly finalized MVP?

Qualified registries and QCDRs get one year to fully support a newly finalized MVP. The Advancing Cancer Care MVP is not new. Registries reporting oncology data must support it now.

Is the CAHPS for MIPS Survey useful for an oncology group?

It can be. The CAHPS for MIPS Survey (#321) is a quality option inside the Advancing Cancer Care MVP. CMS added a web-based survey mode to raise response rates.

Can nurse practitioners and physician assistants report the cancer MVP?

Yes. CMS lists nurse practitioners, physician assistants, and other nonphysician practitioners among the most applicable specialties for the Advancing Cancer Care MVP, alongside oncology and hematology.

Compliance note:

This article is for education only. It is not legal, coding, or billing advice. MIPS results depend on your data and CMS benchmarks, and no score is guaranteed. Confirm details in current CMS measure specifications before submission.